|
1
|
Lee HJ, Song IC, Yun HJ, Jo DY and Kim S:
CXC chemokines and chemokine receptors in gastric cancer: From
basic findings towards therapeutic targeting. World J
Gastroenterol. 20:1681–1693. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bass AJ, Thorsson V, Shmulevich I,
Reynolds SM, Miller M, Bernard B, Hinoue T, Laird PW, Curtis C,
Shen H, et al: Comprehensive molecular characterization of gastric
adenocarcinoma. Nature. 513:202–209. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Tan P and Yeoh KG: Genetics and molecular
pathogenesis of gastric adenocarcinoma. Gastroenterology.
149:1153–1162.e3. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ang YL, Yong WP and Tan P: Translating
gastric cancer genomics into targeted therapies. Crit Rev Oncol
Hematol. 100:141–146. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Grabsch HI and Tan P: Gastric cancer
pathology and underlying molecular mechanisms. Dig Surg.
30:150–158. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Necula LG, Mambet C, Albulescu R and
Diaconu CC: Epigenetics in gastric carcinogenesis: TET genes as
important players. J Immunoassay Immunochem. 36:445–455. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Thiel A and Ristimäki A: Targeted therapy
in gastric cancer. APMIS. 123:365–372. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bang YJ, Van Cutsem E, Feyereislova A,
Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T,
et al: Trastuzumab in combination with chemotherapy versus
chemotherapy alone for treatment of HER2-positive advanced gastric
or gastro-oesophageal junction cancer (ToGA): A phase 3,
open-label, randomised controlled trial. Lancet. 376:687–697. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lee HJ, Ryu H, Choi YS, Song IC, Yun HJ,
Jo DY and Kim S: Just toxicity, or toxicity as a biomarker of
efficacy of ramucirumab in breast cancer? J Clin Oncol.
33:27122015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Fuchs CS, Tomasek J, Yong CJ, Dumitru F,
Passalacqua R, Goswami C, Safran H, dos Santos LV, Aprile G, Ferry
DR, et al: Ramucirumab monotherapy for previously treated advanced
gastric or gastro-oesophageal junction adenocarcinoma (REGARD): An
international, randomised, multicentre, placebo-controlled, phase 3
trial. Lancet. 383:31–39. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yun HJ, Ryu H, Choi YS, Song IC, Jo DY,
Kim S and Lee HJ: C-X-C motif receptor 7 in gastrointestinal
cancer. Oncol Lett. 10:1227–1232. 2015.PubMed/NCBI
|
|
13
|
Mburu YK, Wang J, Wood MA, Walker WH and
Ferris RL: CCR7 mediates inflammation-associated tumor progression.
Immunol Res. 36:61–72. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kunkel SL, Strieter RM, Lindley IJ and
Westwick J: Chemokines: New ligands, receptors and activities.
Immunol Today. 16:559–561. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bachelerie F, Ben-Baruch A, Burkhardt AM,
Combadiere C, Farber JM, Graham GJ, Horuk R, Sparre-Ulrich AH,
Locati M, Luster AD, et al: International union of basic and
clinical pharmacology. [corrected]. LXXXIX. Update on the extended
family of chemokine receptors and introducing a new nomenclature
for atypical chemokine receptors. Pharmacol Rev. 66:1–79. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sarvaiya PJ, Guo D, Ulasov I, Gabikian P
and Lesniak MS: Chemokines in tumor progression and metastasis.
Oncotarget. 4:2171–2185. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Arya M, Patel HR and Williamson M:
Chemokines: Key players in cancer. Curr Med Res Opin. 19:557–564.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Verbeke H, Struyf S, Laureys G and Van
Damme J: The expression and role of CXC chemokines in colorectal
cancer. Cytokine Growth Factor Rev. 22:345–358. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Verbeke H, Geboes K, Van Damme J and
Struyf S: The role of CXC chemokines in the transition of chronic
inflammation to esophageal and gastric cancer. Biochim Biophys
Acta. 1825:117–129. 2012.PubMed/NCBI
|
|
20
|
Luster AD: Chemokines-chemotactic
cytokines that mediate inflammation. N Engl J Med. 338:436–445.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ali S and Lazennec G: Chemokines: Novel
targets for breast cancer metastasis. Cancer Metastasis Rev.
26:401–420. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Weitzenfeld P and Ben-Baruch A: The
chemokine system, and its CCR5 and CXCR4 receptors, as potential
targets for personalized therapy in cancer. Cancer Lett. 352:36–53.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Vandercappellen J, Van Damme J and Struyf
S: The role of CXC chemokines and their receptors in cancer. Cancer
Lett. 267:226–244. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tazzyman S, Lewis CE and Murdoch C:
Neutrophils: Key mediators of tumour angiogenesis. Int J Exp
Pathol. 90:222–231. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Strieter RM, Polverini PJ, Kunkel SL,
Arenberg DA, Burdick MD, Kasper J, Dzuiba J, Van Damme J, Walz A,
Marriott D, et al: The functional role of the ELR motif in CXC
chemokine-mediated angiogenesis. J Biol Chem. 270:27348–27357.
1995. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Strieter RM, Burdick MD, Gomperts BN,
Belperio JA and Keane MP: CXC chemokines in angiogenesis. Cytokine
Growth Factor Rev. 16:593–609. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Arigami T, Natsugoe S, Uenosono Y,
Yanagita S, Arima H, Hirata M, Ishigami S and Aikou T: CCR7 and
CXCR4 expression predicts lymph node status including
micrometastasis in gastric cancer. Int J Oncol. 35:19–24. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Deguchi K, Ichikawa D, Soga K, Watanabe K,
Kosuga T, Takeshita H, Konishi H, Morimura R, Tsujiura M, Komatsu
S, et al: Clinical significance of vascular endothelial growth
factors C and D and chemokine receptor CCR7 in gastric cancer.
Anticancer Res. 30:2361–2366. 2010.PubMed/NCBI
|
|
29
|
Ishigami S, Natsugoe S, Nakajo A, Tokuda
K, Uenosono Y, Arigami T, Matsumoto M, Okumura H, Hokita S and
Aikou T: Prognostic value of CCR7 expression in gastric cancer.
Hepatogastroenterology. 54:1025–1028. 2007.PubMed/NCBI
|
|
30
|
Kwak MK, Hur K, Park DJ, Lee HJ, Lee HS,
Kim WH, Lee KU, Choe KJ and Yang HK: Expression of chemokine
receptors in human gastric cancer. Tumour Biol. 26:65–70. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Mashino K, Sadanaga N, Yamaguchi H, Tanaka
F, Ohta M, Shibuta K, Inoue H and Mori M: Expression of chemokine
receptor CCR7 is associated with lymph node metastasis of gastric
carcinoma. Cancer Res. 62:2937–2941. 2002.PubMed/NCBI
|
|
32
|
Wang WN, Chen Y, Zhang YD and Hu TH: The
regulatory mechanism of CCR7 gene expression and its involvement in
the metastasis and progression of gastric cancer. Tumour Biol.
34:1865–1871. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yan C, Zhu ZG, Yu YY, Ji J, Zhang Y, Ji
YB, Yan M, Chen J, Liu BY, Yin HR and Lin YZ: Expression of
vascular endothelial growth factor C and chemokine receptor CCR7 in
gastric carcinoma and their values in predicting lymph node
metastasis. World J Gastroenterol. 10:783–790. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhou S, Shen Z, Wang Y, Ma H, Xu S, Qin J,
Chen L, Tao H, Zhen Z, Chen G, et al: CCR7 expression and
intratumoral FOXP3+ regulatory T cells are correlated with overall
survival and lymph node metastasis in gastric cancer. PLoS One.
8:e744302013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Schmausser B, Endrich S, Brändlein S,
Schär J, Beier D, Müller-Hermelink HK and Eck M: The chemokine
receptor CCR7 is expressed on epithelium of non-inflamed gastric
mucosa, Helicobacter pylori gastritis, gastric carcinoma and its
precursor lesions and up-regulated by H. pylori. Clin Exp Immunol.
139:323–327. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Chang WJ, Du Y, Zhao X, Ma LY and Cao GW:
Inflammation-related factors predicting prognosis of gastric
cancer. World J Gastroenterol. 20:4586–4596. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Pituch-Noworolska A, Drabik G, Szatanek R,
Białas M, Kołodziejczyk P, Szczepanik A, Stachura J and Zembala M:
Immunophenotype of isolated tumour cells in the blood, bone marrow
and lymph nodes of patients with gastric cancer. Pol J Pathol.
58:93–97. 2007.PubMed/NCBI
|
|
38
|
Chen J, Yang J, Jiang J, Zhuang Y and He
W: Function and subsets of dendritic cells and natural killer cells
were decreased in gastric cancer. Int J Clin Exp Pathol.
7:8304–8311. 2014.PubMed/NCBI
|
|
39
|
Mégraud F, Bessède E and Varon C:
Helicobacter pylori infection and gastric carcinoma. Clin Microbiol
Infect. 21:984–990. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Fehlings M, Drobbe L, Moos V, Viveros P
Renner, Hagen J, Beigier-Bompadre M, Pang E, Belogolova E, Churin
Y, Schneider T, et al: Comparative analysis of the interaction of
Helicobacter pylori with human dendritic cells, macrophages, and
monocytes. Infect Immun. 80:2724–2734. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Moschovakis GL and Förster R: Multifaceted
activities of CCR7 regulate T-cell homeostasis in health and
disease. Eur J Immunol. 42:1949–1955. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Raju R, Gadakh S, Gopal P, George B,
Advani J, Soman S, Prasad TS and Girijadevi R: Differential
ligand-signaling network of CCL19/CCL21-CCR7 system. Database
(Oxford). 2015:pii: bav1062015. View Article : Google Scholar
|
|
43
|
Kodama J, Hasengaowa, Seki N, Kusumoto T
and Hiramatsu Y: Expression of the CXCR4 and CCR7 chemokine
receptors in human endometrial cancer. Eur J Gynaecol Oncol.
28:370–375. 2007.PubMed/NCBI
|
|
44
|
Zhang J, Zhou Y and Yang Y: CCR7 pathway
induces epithelial-mesenchymal transition through up-regulation of
Snail signaling in gastric cancer. Med Oncol. 32:4672015.PubMed/NCBI
|
|
45
|
Ma H, Gao L, Li S, Qin J, Chen L, Liu X,
Xu P, Wang F, Xiao H, Zhou S, et al: CCR7 enhances TGF-β1-induced
epithelial-mesenchymal transition and is associated with lymph node
metastasis and poor overall survival in gastric cancer. Oncotarget.
6:24348–24360. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Sallusto F and Baggiolini M: Chemokines
and leukocyte traffic. Nat Immunol. 9:949–952. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Hughes A and Nelson M: HIV entry: New
insights and implications for patient management. Curr Opin Infect
Dis. 22:35–42. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Soria G and Ben-Baruch A: The inflammatory
chemokines CCL2 and CCL5 in breast cancer. Cancer Lett.
267:271–285. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Lazennec G and Richmond A: Chemokines and
chemokine receptors: New insights into cancer-related inflammation.
Trends Mol Med. 16:133–144. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Mantovani A, Savino B, Locati M, Zammataro
L, Allavena P and Bonecchi R: The chemokine system in cancer
biology and therapy. Cytokine Growth Factor Rev. 21:27–39. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Balkwill FR: The chemokine system and
cancer. J Pathol. 226:148–157. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
González-Martín A, Gómez L, Lustgarten J,
Mira E and Mañes S: Maximal T cell-mediated antitumor responses
rely upon CCR5 expression in both CD4(+) and CD8(+) T cells. Cancer
Res. 71:5455–5466. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
González-Martin A, Mira E and Mañes S:
CCR5 as a potential target in cancer therapy: Inhibition or
stimulation? Anticancer Agents Med Chem. 12:1045–1057. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Lin S, Wan S, Sun L, Hu J, Fang D, Zhao R,
Yuan S and Zhang L: Chemokine C-C motif receptor 5 and C-C motif
ligand 5 promote cancer cell migration under hypoxia. Cancer Sci.
103:904–912. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Hartmann MC, Dwyer RM, Costello M, Potter
SM, Curran C, Hennessy E, Newell J, Griffin DG and Kerin MJ:
Relationship between CCL5 and transforming growth factor-β1 (TGFβ1)
in breast cancer. Eur J Cancer. 47:1669–1675. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Zhang Y, Yao F, Yao X, Yi C, Tan C, Wei L
and Sun S: Role of CCL5 in invasion, proliferation and proportion
of CD44+/CD24- phenotype of MCF-7 cells and correlation of CCL5 and
CCR5 expression with breast cancer progression. Oncol Rep.
21:1113–1121. 2009.PubMed/NCBI
|
|
57
|
Niwa Y, Akamatsu H, Niwa H, Sumi H, Ozaki
Y and Abe A: Correlation of tissue and plasma RANTES levels with
disease course in patients with breast or cervical cancer. Clin
Cancer Res. 7:285–289. 2001.PubMed/NCBI
|
|
58
|
Yaal-Hahoshen N, Shina S, Leider-Trejo L,
Barnea I, Shabtai EL, Azenshtein E, Greenberg I, Keydar I and
Ben-Baruch A: The chemokine CCL5 as a potential prognostic factor
predicting disease progression in stage II breast cancer patients.
Clin Cancer Res. 12:4474–4480. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Cao Z, Xu X, Luo X, Li L, Huang B, Li X,
Tao D, Hu J and Gong J: Role of RANTES and its receptor in gastric
cancer metastasis. J Huazhong Univ Sci Technolog Med Sci.
31:342–347. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Lin SS, Fan W, Sun L, Li FF, Zhao RP,
Zhang LY, Yu BY and Yuan ST: The saponin DT-13 inhibits gastric
cancer cell migration through down-regulation of CCR5-CCL5 axis.
Chin J Nat Med. 12:833–840. 2014.PubMed/NCBI
|
|
61
|
Mencarelli A, Graziosi L, Renga B,
Cipriani S, D'Amore C, Francisci D, Bruno A, Baldelli F, Donini A
and Fiorucci S: CCR5 antagonism by maraviroc reduces the potential
for gastric cancer cell dissemination. Transl Oncol. 6:784–793.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Sugasawa H, Ichikura T, Tsujimoto H,
Kinoshita M, Morita D, Ono S, Chochi K, Tsuda H, Seki S and
Mochizuki H: Prognostic significance of expression of CCL5/RANTES
receptors in patients with gastric cancer. J Surg Oncol.
97:445–450. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Gawron AJ, Fought AJ, Lissowska J, Ye W,
Zhang X, Chow WH, Freeman LE Beane and Hou L: Polymorphisms in
chemokine and receptor genes and gastric cancer risk and survival
in a high risk Polish population. Scand J Gastroenterol.
46:333–340. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Ding H, Zhao L, Dai S, Li L, Wang F and
Shan B: CCL5 secreted by tumor associated macrophages may be a new
target in treatment of gastric cancer. Biomed Pharmacother.
77:142–149. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Okita K, Furuhata T, Kimura Y, Kawakami M,
Yamaguchi K, Tsuruma T, Zembutsu H and Hirata K: The interplay
between gastric cancer cell lines and PBMCs mediated by the CC
chemokine RANTES plays an important role in tumor progression. J
Exp Clin Cancer Res. 24:439–446. 2005.PubMed/NCBI
|
|
66
|
Shi M, Chen D, Yang D and Liu XY:
CCL21-CCR7 promotes the lymph node metastasis of esophageal
squamous cell carcinoma by up-regulating MUC1. J Exp Clin Cancer
Res. 34:1492015. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Alfonso-Pérez M, López-Giral S, Quintana
NE, Loscertales J, Martín-Jiménez P and Muñoz C: Anti-CCR7
monoclonal antibodies as a novel tool for the treatment of chronic
lymphocyte leukemia. J Leukoc Biol. 79:1157–1165. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Cuesta-Mateos C, Loscertales J, Kreutzman
A, Colom-Fernández B, Portero-Sáinz I, Pérez-Villar JJ, Terrón F
and Muñoz-Calleja C: Preclinical activity of anti-CCR7
immunotherapy in patients with high-risk chronic lymphocytic
leukemia. Cancer Immunol Immunother. 64:665–676. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Somovilla-Crespo B, Alfonso-Pérez M,
Cuesta-Mateos C, Carballo-de Dios C, Beltrán AE, Terrón F,
Pérez-Villar JJ, Gamallo-Amat C, Pérez-Chacón G, Fernández-Ruiz E,
et al: Anti-CCR7 therapy exerts a potent anti-tumor activity in a
xenograft model of human mantle cell lymphoma. J Hematol Oncol.
6:892013. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Boyle ST, Ingman WV, Poltavets V, Faulkner
JW, Whitfield RJ, McColl SR and Kochetkova M: The chemokine
receptor CCR7 promotes mammary tumorigenesis through amplification
of stem-like cells. Oncogene. 35:105–115. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Kim SJ, Shin JY, Lee KD, Bae YK, Sung KW,
Nam SJ and Chun KH: MicroRNA let-7a suppresses breast cancer cell
migration and invasion through downregulation of C-C chemokine
receptor type 7. Breast Cancer Res. 14:R142012. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Ruan J, Ji J, Song H, Qian Q, Wang K, Wang
C and Cui D: Fluorescent magnetic nanoparticle-labeled mesenchymal
stem cells for targeted imaging and hyperthermia therapy of in vivo
gastric cancer. Nanoscale Res Lett. 7:3092012. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Cambien B, Richard-Fiardo P, Karimdjee BF,
Martini V, Ferrua B, Pitard B, Schmid-Antomarchi H and
Schmid-Alliana A: CCL5 neutralization restricts cancer growth and
potentiates the targeting of PDGFRβ in colorectal carcinoma. PLoS
One. 6:e288422011. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Velasco-Velázquez M, Jiao X, De La Fuente
M, Pestell TG, Ertel A, Lisanti MP and Pestell RG: CCR5 antagonist
blocks metastasis of basal breast cancer cells. Cancer Res.
72:3839–3850. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Velasco-Velázquez M, Xolalpa W and Pestell
RG: The potential to target CCL5/CCR5 in breast cancer. Expert Opin
Ther Targets. 18:1265–1275. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Che LF, Shao SF and Wang LX:
Downregulation of CCR5 inhibits the proliferation and invasion of
cervical cancer cells and is regulated by microRNA-107. Exp Ther
Med. 11:503–509. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Maeda K, Das D, Nakata H and Mitsuya H:
CCR5 inhibitors: Emergence, success, and challenges. Expert Opin
Emerg Drugs. 17:135–145. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Ochoa-Callejero L, Pérez-Martínez L,
Rubio-Mediavilla S, Oteo JA, Martínez A and Blanco JR: Maraviroc, a
CCR5 antagonist, prevents development of hepatocellular carcinoma
in a mouse model. PLoS One. 8:e539922013. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Tan MC, Goedegebuure PS, Belt BA, Flaherty
B, Sankpal N, Gillanders WE, Eberlein TJ, Hsieh CS and Linehan DC:
Disruption of CCR5-dependent homing of regulatory T cells inhibits
tumor growth in a murine model of pancreatic cancer. J Immunol.
182:1746–1755. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Robinson SC, Scott KA, Wilson JL, Thompson
RG, Proudfoot AE and Balkwill FR: A chemokine receptor antagonist
inhibits experimental breast tumor growth. Cancer Res.
63:8360–8365. 2003.PubMed/NCBI
|
|
81
|
Sutton A, Friand V, Papy-Garcia D,
Dagouassat M, Martin L, Vassy R, Haddad O, Sainte-Catherine O,
Kraemer M, Saffar L, et al: Glycosaminoglycans and their synthetic
mimetics inhibit RANTES-induced migration and invasion of human
hepatoma cells. Mol Cancer Ther. 6:2948–2958. 2007. View Article : Google Scholar : PubMed/NCBI
|
